Which company's drug is Carpisetin/Tunicotide and who is the manufacturer?

Capivasertib is a new oral AKT inhibitor developed by AstraZeneca for patients with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. The drug was approved by the US FDA in November 2023 and approved by the EU EMA in June 2024. Its listing marks the entry into clinical application of new targeted therapeutic drugs targeting the PI3K/AKT signaling pathway.

The main body of R&D and production of carpisetin is AstraZeneca (AstraZeneca), a global biopharmaceutical company headquartered in Cambridge, UK, known for its innovative drug research and development and precision medical solutions. AstraZeneca focuses on drug development for oncology, cardiovascular, respiratory and immune diseases globally. Its R&D system includes in-house research teams and cooperation with multiple academic institutions.

The research and development of carpisetin was first initiated by AstraZeneca in cooperation withAstex Pharmaceuticals. Astex has extensive experience in the research and development of cancer targeted drugs, especially providing technical support in the design of small molecule inhibitors. Capivasertib has been fully managed by AstraZeneca's global R&D network during the clinical development process, from early pharmacology studies, dose optimization to large-scale Phase III clinical trials, which reflects AstraZeneca's strength in the field of precision tumor targeted therapy.

After the drug is launched, AstraZeneca is responsible for global production, supply and distribution, and is also conducting marketing and education to ensure that clinicians can rationally select patients and use the drug safely. As a global pharmaceutical giant, AstraZeneca's production management system and regulatory experience enable capizetid to be successfully launched in different countries and regions, and may expand the scope of indications in the future, including prostate cancer and other AKT pathway-related tumors, providing solid support for the development of precision medicine.

Reference materials:https://www.drugs.com/mtm/capivasertib.html